Tafasitamab

坦昔妥单抗

Report date: 2026/04/23 17:15:56
First In Class

Base Information

Drug NameTafasitamab
Drug Alias NameTafasitamab-cxixMONJUVIMinjuvi明诺凯XmAb-5574 +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPurpura, Thrombocytopenic, IdiopathicHematologic NeoplasmsLymphoma, Follicular +[7] 
Global Approved IndicationsLymphoma, FollicularLymphoma, Large B-Cell, Diffuse
Approved Indications in ChinaLymphoma, Large B-Cell, Diffuse
Original Approved Country/TerritoryUnited States
Original Approved Date2020/07/31
Country/TerritoryMainland China(BOAO LECHENG)CzechiaBelgium +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesXencor Inc
China Registration ClassN/A

Develop Information

Active CompaniesSpecialised Therapeutics AustraliaKnight TherapeuticsIncyte Inc +[11] 
Inactive CompaniesBaxter Oncology GmbhXencor IncInnoCare Pharma Ltd
Active IndicationsPurpura, Thrombocytopenic, IdiopathicHematologic NeoplasmsLymphoma, Follicular +[6] 
Inactive IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG